Confined or spread disease-Spread into the peritoneum Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread into the peritoneum Posts on Medivizor

Comparing the safety and effectiveness of regorafenib versus TAS-102 for the treatment of patients with unresponsive metastatic colorectal cancer.

Comparing the safety and effectiveness of regorafenib versus TAS-102 for the treatment of patients with unresponsive metastatic colorectal cancer.

Posted by on Aug 7, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of regorafenib (Stivarga) versus TAS-102 (Lonsurf; trifluridine-tipiracil) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that both treatments were safe and lead to similar survival outcomes for primary and secondary treatment of...

Read More

Evaluating surgery and chemotherapy versus chemotherapy alone for the treatment of metastatic colorectal cancer.

Evaluating surgery and chemotherapy versus chemotherapy alone for the treatment of metastatic colorectal cancer.

Posted by on Mar 31, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated whether surgery of colorectal cancer (CRC) followed by chemotherapy (CT) improved the outcomes of patients with metastatic (spread) CRC compared to CT alone. The study found that there was no difference in patients' outcomes whether surgery was given or not. Some background CRC is the third most common cancer...

Read More

Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer

Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer

Posted by on Sep 30, 2020 in Colorectal cancer | 0 comments

In a nutshell This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients. Some...

Read More

Looking for patients with advanced colorectal cancer to test an experimental treatment

Looking for patients with advanced colorectal cancer to test an experimental treatment

Posted by on Sep 10, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as colorectal cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Searching for patients with advanced colorectal cancer to test a new combination therapy

Posted by on Aug 22, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In many...

Read More

Looking for patients with advanced colorectal cancer to test a new drug

Looking for patients with advanced colorectal cancer to test a new drug

Posted by on Jun 28, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced colorectal cancer and other solid tumors.  The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details...

Read More

Looking patients with advanced cancer to test a new immunotherapy combination

Posted by on May 31, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...

Read More

Looking for participants to test a new treatment combination for advanced colorectal cancer

Looking for participants to test a new treatment combination for advanced colorectal cancer

Posted by on Apr 17, 2019 in Colorectal cancer | 0 comments

In a nutshell This trial is examining the effectiveness and safety of treatment with nivolumab (Opdivo) and relatlimab in patients with advanced colorectal cancer. The main outcome to be measured will be tumor response to the treatment. This trial is being conducted in Maryland, US. The details Colorectal cancer is the third most common cancer in the...

Read More

Can CEA levels predict tumor response to treatment in advanced colorectal cancer?

Can CEA levels predict tumor response to treatment in advanced colorectal cancer?

Posted by on Feb 12, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the relationship between changes in the levels of carcinoembryonic antigen (CEA) and colorectal cancer response to treatment. Researchers suggested that CEA levels are associated with tumor response and can be used as a prognostic factor. Some background In 2014 the European Society for Medical Oncology...

Read More

Looking for patients with advanced colorectal cancer to a test two different treatment combinations

Looking for patients with advanced colorectal cancer to a test two different treatment combinations

Posted by on Jan 31, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 3 trial is examining the effectiveness of arfolitixorin versus leucovorin (folinic acid) when added to a combined treatment with 5-fluorouracil, oxaliplatin, and bevacizumab (FOB) to treat advanced colorectal cancer. The main outcome to be measured is the cancer response to the treatment. The details Treatment with...

Read More

Evaluating Cetuximab plus FOLFOX-4 chemotherapy for patients with metastatic colorectal cancer

Evaluating Cetuximab plus FOLFOX-4 chemotherapy for patients with metastatic colorectal cancer

Posted by on Oct 13, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of cetuximab (Erbitux) combined with FOLFOX-4 (leucovorin, fluorouracil, and oxaliplatin) chemotherapy to treat metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment is associated with improved cancer outcomes. Some background...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor